How long will the good times roll for medtech?
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Prescription apps take off during lockdown
Digital therapeutics are going from strength to strength during the pandemic.
One step forward, two steps back for prescription apps
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
